You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

369 Results
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    encorafenib - In combination with cetuximab or panitumumab in previously treated BRAF V600E-mutated metastatic colorectal cancer, according to clinical criteria
New Drug Funding Program
    Cetuximab - In Combination with Encorafenib for Previously Treated Metastatic Colorectal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
encorafenib,
cetuximab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024
Guidelines and Advice
Status: Current
ID: PET 2020-1
Version: N/A
Nov 2020
Guidelines and Advice
Status: Current
Version: 1.0
Dec 2020
Document
Feb 2021
Document
Feb 2021
Document
Mar 2021
Document
Mar 2021
Document
Mar 2021
Document
Mar 2021
Document
Apr 2021
Guidelines and Advice
Status: Current
Jun 2021
Guidelines and Advice
Status: Current
ID: PET 2020-2
May 2021

Pages